Rekombinant Anti-Melanoma Antikörper [rMLANA/8180] (A315296)

Anti-Melanoma Antibody [rMLANA/8180]

Recombinant mouse monoclonal [rMLANA/8180] antibody to Melanoma.

This antibody recognizes a protein doublet of 20-22kDa, identified as MART-1 (Melanoma Antigen Recognized by T cells 1) or Melan-A. MART-1 is a newly identified melanocyte differentiation antigen recognized by autologous cytotoxic T lymphocytes. Seven other melanoma associated antigens recognized by autologous cytotoxic T cells include MAGE-1, MAGE-3, tyrosinase, gp100, gp75, BAGE-1, and GAGE-1. Subcellular fractionation shows that MART-1 is present in melanosomes and endoplasmic reticulum. This MAb labels melanomas and other tumors showing melanocytic differentiation. It is also a useful positive-marker for angiomyolipomas. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin.

IHC-P

SK-MEL-13 or SK-MEL-19 melanoma cell lines. Melanomas.

IHC: 1-2 µg/ml

Human

Recombinant full-length human MART-1 protein.

Mouse

Monoclonal

rMLANA/8180

kappa

Unconjugated

Protein A/G chromatography.

200 µg/ml

20-22 kDa (doublet)

Liquid

Supplied in 10mM Phosphate Buffered Saline with 0.05% BSA and 0.05% Sodium Azide.

Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

Antigen LB39 AA, Antigen SK29 AA, MART1, melan A, Melan A protein, Melanoma antigen recognized by T-cells 1 , Monophenol monooxygenase, Tumor rejection antigen AB, tyrosinase